Compare Charles River Laboratories Intl. Inc (CRL) vs iShares Broad USD Investment Grade Corporate Bond (USIG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs iShares Broad USD Investment Grade Corporate Bond — how do they compare? Charles River Laboratories Intl. Inc trades at $288.87 (market cap $13.46B), while iShares Broad USD Investment Grade Corporate Bond trades at $50.25. The key difference: Charles River Laboratories Intl. Inc is trading nearer its 52-week high, iShares Broad USD Investment Grade Corporate Bond nearer its low. Which is the better fit depends on your goals.
| CRL | USIG | |
|---|---|---|
Market Cap | $13.46B | — |
Sector | Health | Fixed Income |
52-Week High | $282.00 | $52.69 |
52-Week Low | $145.57 | $50.18 |
Enterprise Value | $16.30B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $284.37, up 2.66% today and near its 52-week high, reflecting strong bullish momentum. The stock has consistently beaten earnings estimates in recent quarters, including a Q2 2026 EPS of $3.02 versus $2.77 expected, and the company raised its full-year guidance. Despite negative net income margins, operating cash flow remains robust at $738 million in 2025. Analyst sentiment is overwhelmingly positive with 26 buy ratings and a consensus price target of $277.29.
The outlook is supported by improving biotech demand and cost controls, but high valuation multiples and recent insider selling pose risks. Earnings growth and margin expansion are key catalysts, though profitability challenges and macroeconomic sensitivity could pressure the stock. Investors should weigh strong technicals and analyst support against fundamental weaknesses and execution risks.
USIG trades at $50.25, up 0.14% on the day, with a bearish technical signal driven by moving averages and neutral oscillators. Recent news includes a transaction with Tiptree Inc. and increased institutional interest from Bank of New York Mellon Corp. The stock shows consistent dividend payments, with three recent distributions totaling $0.62 per share through mid-2026.
The outlook remains cautious due to weak technical momentum and limited fundamental data visibility. Risks include reliance on corporate bond market stability and competitive pressures in the insurance sector. Analyst sentiment is neutral, with institutional accumulation suggesting long-term confidence amid near-term headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About iShares Broad USD Investment Grade Corporate Bond
USIG is a low-cost ETF providing broad exposure to over 11,000 U.S. investment-grade corporate bonds. It tracks the ICE BofA US Corporate Index, featuring high-quality debt from 2026 leaders like Citigroup, Bank of America, and Oracle.
Read more on USIG →
